About Debiopharm
Debiopharm is a company based in Lausanne (Switzerland) founded in 1979. Debiopharm has completed 1 acquisition, including Affinium Pharmaceuticals. Debiopharm offers products and services including Drug Development Services, Manufacturing Services, and Innovation Fund. Debiopharm operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Debiopharm International
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Debiopharm
Debiopharm offers a comprehensive portfolio of products and services, including Drug Development Services, Manufacturing Services, and Innovation Fund.
Develops compounds for oncology and infections through partnerships.
Produces drugs for development and commercialization processes.
Invests in digital health and smart data start-ups globally.
Funding Insights of Debiopharm
Investors in Debiopharm
Debiopharm has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Locked | Locked | Locked |
Investor details for Debiopharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Debiopharm
Debiopharm has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Affinium Pharmaceuticals.
Investment portfolio details for Debiopharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Debiopharm
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Debiopharm
Detailed financials for Debiopharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Debiopharm Comparisons
Peer comparison for Debiopharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Debiopharm
Debiopharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Debiopharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Debiopharm
Complete news archive for Debiopharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Debiopharm
Debiopharm was founded in 1979 and raised its 1st funding round 40 years after it was founded.
Debiopharm is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs. The lead drug candidates are Xevinapant for cancer, Afabicin for orthopedics, Alisporivir for cOVID and GI disorders, Debio 1450, ABSSSI, for staph infections.
Debiopharm's top competitors include Merck, Roivant Sciences and AbbVie.
Debiopharm offers Drug Development Services, Manufacturing Services, and Innovation Fund.
Debiopharm has made 1 acquisition, including Affinium Pharmaceuticals.
Debiopharm has 1 investor. Key investors include CARB-X.